Biovail Announces Third-Quarter 2009 Earnings Release, Conference-Call Details.TORONTO -- Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency ) (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :BVF) today announced that it will host a conference call and webcast on Thursday, November 5, 2009 at 8:30a.m. for Company executives to discuss third-quarter 2009 financial and operational results. Following the discussion, Biovail executives will address inquiries from investment analysts. A live webcast of this call will be available through the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of Biovail's website at www.biovail.com. To access the call live, please dial 416-340-8427 (Toronto and International callers) and 1-866-225-2055 (U.S. and Canada). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 7:00p.m. ET on Thursday, November 12, 2009 by dialing 416-695-5800 (Toronto and International callers) and 1-800-408-3053 (U.S. and Canada), using access code: 2777843#. About Biovail Corporation Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet un·met adj. Not satisfied or fulfilled: unmet demands. medical needs in niche specialty central nervous system (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) markets. For more information about Biovail, visit the Company's Web site at www.biovail.com. For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com. |
|
||||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion